Liqiang Xi, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 3S249
- Bethesda, MD 20892-1500
- 301-480-8933
- xil2@mail.nih.gov
RESEARCH SUMMARY
Dr. Xi worked with a translational clinical research team for 8 years at the University of Pittsburgh School of Medicine and later at the Mount Sinai School of Medicine, New York. This research was focused on identification of molecular markers to reliably detect cancer metastasis to lymph nodes or blood, and on molecular signatures of cancer by employing the cutting-edge technologies at the time, such as TaqMan real-time quantitative RT-PCR, gene expression microarrays, microRNA expression profiling, and genome wide whole exon microarrays.
At the NCI, Dr. Xi serves as the technical director for the Molecular Diagnostics Laboratory, Laboratory of Pathology, supervising a broad array of CLIA-certified molecular diagnostics activities from traditional fragment analysis for detection of B cell and T cell clonality in lymphoma and RT-PCR assays for fusion gene detection in sarcoma, to cancer gene mutation testing using the most cutting-edge technology, next generation sequencing.
Areas of Expertise
Liqiang Xi, M.D.
Research
Dr. Xi worked with a translational clinical research team for 8 years at the University of Pittsburgh School of Medicine and later at the Mount Sinai School of Medicine, New York. This research was focused on identification of molecular markers to reliably detect cancer metastasis to lymph nodes or blood, and on molecular signatures of cancer by employing the cutting-edge technologies at the time, such as TaqMan real-time quantitative RT-PCR, gene expression microarrays, microRNA expression profiling, and genome wide whole exon microarrays.
At the NCI, Dr. Xi serves as the technical director for the Molecular Diagnostics Laboratory, Laboratory of Pathology, supervising a broad array of CLIA-certified molecular diagnostics activities from traditional fragment analysis for detection of B cell and T cell clonality in lymphoma and RT-PCR assays for fusion gene detection in sarcoma, to cancer gene mutation testing using the most cutting-edge technology, next generation sequencing.
In addition to research and development of new molecular tests that support molecular diagnostics and personalized cancer therapies, Dr. Xi's research interests currently focus on analysis of circulating tumor DNA in melanoma to measure the immunotherapy response, and targeted mutational analysis of uncommon types of lymphoma.
Publications
Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas
Circulating Tumor DNA as an Early Indicator of Response to T-Cell Transfer Immunotherapy in Metastatic Melanoma
Somatic STAT5b gain of function mutations in early-onset non-clonal eosinophilia, urticaria, dermatitis and diarrhea
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations
Biography
Liqiang Xi, M.D.
Dr. Xi completed his medical education in China. He obtained his M.S. in toxicology and occupational health from the Chinese Center for Disease Control and Prevention. He pursued postdoctoral training at the UC Berkeley School of Public Health and the University of Pittsburgh Graduate School of Public Health, where he studied biomarkers of environmental carcinogenesis. While in Pittsburgh he also studied and obtained his M.S. in information science with a focus in bioinformatics. Prior to joining the NCI Laboratory of Pathology, Dr. Xi was a research assistant professor at the Department of Pathology, Mount Sinai School of Medicine, New York. He has co-authored 2 patents and over 60 scientific publications.